Published On: Tue, Oct 1st, 2013

Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration

The Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration, compared to placebo in MRI analyses.

 

DRUG mortazavi20120315100616023


Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today the publication of a pre-planned analysis of the Phase III ALLEGRO study demonstrating that once-daily oral laquinimod provides a beneficial impact on brain tissue damage, one of the most destructive aspects of multiple sclerosis.
These data, “Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage, ” published online in September by the Journal of Neurology, Neurosurgery & Psychiatry (JNNP),

“These analyses reinforce our faith in the potential of laquinimod and we are proud to announce that we plan to initiate a clinical trial of the drug in PPMS to gather even more evidence of this novel mechanism of action, ” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer for Teva Pharmaceutical Industries Ltd. “ We also believe the potential neuroprotective benefits of laquinimod could have significant application in the treatment of other diseases like Crohn’s disease, lupus nephritis, Huntington’s disease and Alzheimer’s.”

 

About Laquinimod 

Laquinimod is an oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of relapsing-remitting MS (RRMS).
In addition , laquinimod is currently in Phase II of development for Crohn’s disease and lupus nephritis. Because of the neuroprotective findings, Teva is evaluating further studies to determine the effectiveness of laquinimod in treating patients with primary progressive multiple sclerosis, Huntington’s disease and Alzheimer’s disease.

 

 

 

Read more about: , , , , , ,

Wordpress site Developed by Fixing WordPress Problems